Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02623569
Other study ID # A130901CSPF01
Secondary ID
Status Recruiting
Phase Phase 2
First received November 29, 2015
Last updated December 4, 2015
Start date October 2014
Est. completion date June 2017

Study information

Verified date December 2015
Source Xintong Pharmacy Company
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Arms Assigned Interventions

Experimental: Ivabradine Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR>60times/min or negative ETT and HR>80times/min of subjects.

Active Comparator: Atenolol Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and heard rate>60times/min or negative ETT and HR >80times/min of subjects.


Description:

1. Washout period:Chronic angina patients stop using medicine that affect heart rate. The patients undergoes ETT after 2-7 days and positive ETT into the treatment period(If not take similar medicine, patients can be carried out ETT directly)。

2. Treatment period:Patients carried out ETT after therapy with Ivabradine(5mg,bid)/ Atenolol(12.5mg,bid) for 4 weeks.The dose adjust base on test result and heart rate, Ivabradine(5mg,bid)/Atenolol(12.5mg,bid) or Ivabradine(7.5mg,bid)/ Atenolol(25mg,bid) for 8 weeks and carried out ETT.

3. security period:After the treatment period, all patients to take Atenolol 12.5mg/ 25mg bid 1 week.

If heart rate are low 50 times/min after taking Ivabradine 5mg/ Atenolol 12.5mg, subjects should withdrawal and dropped out study. If subjects heart rate are low 50 times/min after taking Ivabradine 7.5mg/ Atenolol 25mg, subjects should change the dose to Ivabradine 5mg/ Atenolol 12.5mg.


Recruitment information / eligibility

Status Recruiting
Enrollment 336
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. male or female aged 18 to 75 years

2. Clearly understand the study and participate in it voluntarily; the informed consent should be signed in person or by legal guardian.

3. Chronic Stable Angina was confirmed by clinic over 3 months.

4. Patients with clinical diagnosis of chronic stable angina and must meet one of the following conditions:

- Patients who have a history of myocardial infarction over 3 months.

- Patients who have received coronary intervention or CABG(Coronary Artery Bypass Grafting) over 6 months.

- Stenosis of more than 50% in at least one major epicardial coronary artery shown by Coronary Angiograph.

- Ischemic electrocardiogram changes:ST-segment depression = 1.0 mm compared with P-R or elevate=1.0 mm during exercise ECG Computed Tomography Angiography (CTA) showed more than 50% stenosis with typical angina symptoms

5. ultrasonic cardiogram disclosed that left ventricular ejection fraction =50 %.

6. Patients who manifested positive ETT (exercise tolerance testing) (defined as ST-segment depression = 1 mm compared with at rest, with or without limiting angina) at screening.

Exclusion Criteria:

1. Clinically significant Valvular disease, congenital heart disease, pulmonary hypertension, cerebral apoplexy, dissecting aneurysm, hypertrophic cardiomyopathy, acute myocarditis/cp.

2. Patients with myocardial infarction within the preceding 3 months

3. Patients have received Coronary angioplasty or CABG within the preceding 6 months.

4. Patients who have severity vessels disease with left main coronary artery but have no valid treatment.

5. Patients with congestive heart failure(New York Heart Association class III or IV)or acute pulmonary edema.

6. Patients whose rest heart rate< 60 bpm.

7. Patients with nonrespiratory sinus arrhythmia or arrhythmia(e.g.,AVB(auriculo-ventricular block)??,atrial fibrillation,atrial flutter,SSS(sick sinus syndrome)) or implantable cardiac defibrillator (ICD).

8. Patient with any conditions that interfered the performance of exercise tolerance test or a history of an abnormal exercise response limited by electrocardiograph (ECG) changes.

9. Patient with uncontrolled hypertension (seated systolic blood pressure (SBP)=180 mmHg or diastolic blood pressure (DBP) =100 mmHg); SBP<90 mmHg and/or DBP<60 mmHg

10. Diabetic with uncontrolled blood glucose(FBG=11.1 mmol/L and/or RBG=13.6 mmol/L)

11. Patients with anemia(male:Hb=120 g/L;female:Hb=110 g/L)

12. Patients complicated with systemic diseases included thyroid dysfunction?glaucoma?cataract,neurological?mental?psychological disease and any other disease that influence the judgment.

13. Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.).

14. Patients with mental or legal disorder.

15. Patients who were suspected addicted into alcohol or drug abuse or with severe complications that would make the condition more complicated assessed by the investigator.

16. People have liver or renal dysfunction (ALT=2×ULN?AST=2×ULN?eGFR=60ml/min/1.73m2)

17. Patients who should use unapproved drug during the study.

18. Patients who accepted amiodarone(in recent 3 months)and/or benzetimide?ßblockers(in recent 7 days)?

19. Patients with history of allergy or suspected allergic to the drug(e.g.,Hydrochloric ivabradine,atenolol, ßblockers)or lactose.

20. Woman who disagree with contraception during treatment period ,with pregnancy, lactation or positive result of pregnancy test.

21. Patients with Chronic Obstructive Pulmonary Disease (COPD) requiring bronchodilators.

22. Patients who is participating in other trials or has been participated in other trials in recent 3 months

23. Patients who were unable to participate in the study as judged by investigator.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Ivabradine
Not Provided
Atenolol
Not Provided

Locations

Country Name City State
China Guizhou Provincial People's Hospital Guiyang Guizhou
China Zhongda Hospital Southeast University Nanjing Jiangsu
China The General Hospital of Shenyang Military Shenyang Liaoning

Sponsors (1)

Lead Sponsor Collaborator
Xintong Pharmacy Company

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary efficacy endpoint is Change from total exercise duration in exercise tolerance test (ETT) Baseline and end of treatment (Week 12) . No
Secondary Time to angina in exercise tolerance test. 12 weeks No
Secondary Time to 1 mm ST-segment depression in exercise tolerance test 12 weeks No
Secondary Number of angina attacks in exercise tolerance test per week 12 weeks No
Secondary Number of sublingual nitroglycerin consumption per week 12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting NCT02773615 - CT Perfusion Added to CT Angiography
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Terminated NCT02548611 - Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention Phase 4
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT01425359 - Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina Phase 4
Completed NCT01486030 - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
Completed NCT01604486 - Natural Ischaemic Preconditioning Before First Myocardial Infarction N/A
Completed NCT00811772 - Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis N/A
Completed NCT00131183 - Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Phase 4
Completed NCT00184444 - Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients N/A
Completed NCT00235404 - Randomized Controlled Trial of Health Care to Elderly Patients. N/A
Terminated NCT00157742 - Comparison of SCS and PMR in Patients With Refractory Angina Pectoris Phase 4
Completed NCT00000510 - Platelet-Inhibitor Drug Trial in Coronary Angioplasty Phase 3
Completed NCT00005148 - Coronary Heart Disease Incidence, Mortality, and Risk Factor Relationships N/A
Not yet recruiting NCT03657758 - Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO] Phase 4
Completed NCT05050773 - Registry Study of Medical Therapy in Patients With Angina Pectoris(GREAT)
Completed NCT00093223 - A Safety Study of ABI-007 for In-Stent Restenosis Phase 2
Active, not recruiting NCT02508714 - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents N/A